{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:42Z","timestamp":1792552302309,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T00:00:00Z","timestamp":1389916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40265-013-0170-8","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T08:34:48Z","timestamp":1389861288000},"page":"207-221","source":"Crossref","is-referenced-by-count":83,"title":["Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,17]]},"reference":[{"issue":"4","key":"170_CR1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40265-013-0020-8","volume":"73","author":"B-C Liao","year":"2013","unstructured":"Liao B-C, Lin C-C, Yang JC-H. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013;73(4):357\u201369.","journal-title":"Drugs"},{"issue":"17","key":"170_CR2","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/11597700-000000000-00000","volume":"71","author":"L Bonanno","year":"2011","unstructured":"Bonanno L, Favaretto A, Rugge M. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs. 2011;71(17):2231\u201346.","journal-title":"Drugs"},{"key":"170_CR3","unstructured":"National Comprehensive Cancer Network. Non-small cell lung cancer: NCCN clinical practice guidelines in oncology (version 1.2014). 2013. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf . Accessed 22 Oct 2013."},{"issue":"5","key":"170_CR4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/era.11.34","volume":"11","author":"G Metro","year":"2011","unstructured":"Metro G, Crin\u00f2 L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011;11(5):673\u201382.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"170_CR5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/fon.11.62","volume":"7","author":"V Hirsh","year":"2011","unstructured":"Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 2011;7(7):817\u201325.","journal-title":"Future Oncol"},{"key":"170_CR6","first-page":"135","volume":"6","author":"V Nelson","year":"2013","unstructured":"Nelson V, Ziehr J, Agulnik M, et al. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013;6:135\u201343.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"170_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/thy.10.86","volume":"8","author":"RE Bordoni","year":"2011","unstructured":"Bordoni RE. Afatinib (BIBW-2992): a novel dual EGFR\/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy. 2011;8(1):15\u201322.","journal-title":"Therapy"},{"issue":"1","key":"170_CR8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.lungcan.2011.12.014","volume":"77","author":"W Brugger","year":"2012","unstructured":"Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer. 2012;77(1):2\u20138.","journal-title":"Lung Cancer"},{"key":"170_CR9","unstructured":"Boehringer Ingelheim. New efficacy and safety data adds to evidence supporting treatment with afatinib (Giotrif\u00ae) in Asian and non-Asian lung cancer patients [media release]. 2013. http:\/\/www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2013\/27_october_2013_oncology.html . Accessed 2 Dec 2013."},{"key":"170_CR10","unstructured":"European Medicines Agency. Giotrif (afatinib) film-coated tablets: EU summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002280\/WC500152392.pdf . Accessed 18 Oct 2013."},{"key":"170_CR11","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Gilotrif\u2122 (afatinib) tablets for oral use: US prescribing information. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/201292s000lbl.pdf . Accessed 15 Oct 2013."},{"key":"170_CR12","unstructured":"QIAGEN N.V. QIAGEN submits companion diagnostic to FDA to guide treatment decisions for new investigational lung cancer compound [media release]. 2013. http:\/\/www.qiagen.com . Accessed 23 Oct 2013."},{"key":"170_CR13","unstructured":"QIAGEN N.V. QIAGEN receives FDA approval for therascreen\u00ae EGFR RGQ PCR Kit as a companion diagnostic for lung cancer patients [media release]. 2013. http:\/\/www.qiagen.com . Accessed 23 Oct 2013."},{"issue":"34","key":"170_CR14","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","volume":"27","author":"D Li","year":"2008","unstructured":"Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702\u201311.","journal-title":"Oncogene"},{"issue":"2","key":"170_CR15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342\u201350.","journal-title":"J Pharmacol Exp Ther"},{"key":"170_CR16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1741-7015-10-28","volume":"10","author":"G Chen","year":"2012","unstructured":"Chen G, Kronenberger P, Teugels E, et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.","journal-title":"BMC Med"},{"issue":"6","key":"170_CR17","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1158\/1535-7163.MCT-09-1009","volume":"9","author":"K Takezawa","year":"2010","unstructured":"Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 2010;9(6):1647\u201356.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"170_CR18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/cas.12125","volume":"104","author":"K Furuyama","year":"2013","unstructured":"Furuyama K, Harada T, Iwama E, et al. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci. 2013;104(5):584\u20139.","journal-title":"Cancer Sci"},{"issue":"5","key":"170_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1535-7163.MCT-12-0885","volume":"12","author":"T Ninomiya","year":"2013","unstructured":"Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12(5):589\u201397.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"170_CR20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1535-7163.MCT-11-0750","volume":"11","author":"Y Kim","year":"2012","unstructured":"Kim Y, Ko J, Cui Z-Y, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012;11(3):784\u201391.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"170_CR21","first-page":"3000","volume":"119","author":"L Regales","year":"2009","unstructured":"Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119(10):3000\u201310.","journal-title":"J Clin Invest"},{"issue":"10","key":"170_CR22","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1158\/1535-7163.MCT-12-0311","volume":"11","author":"SM Kim","year":"2012","unstructured":"Kim SM, Kwon O-J, Hong YK, et al. Activation of IL-6R\/JAK1\/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther. 2012;11(10):2254\u201364.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"170_CR23","doi-asserted-by":"crossref","first-page":"e59708","DOI":"10.1371\/journal.pone.0059708","volume":"8","author":"G Chen","year":"2013","unstructured":"Chen G, Noor A, Kronenberger P, et al. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 2013;8(3):e59708.","journal-title":"PLoS One"},{"issue":"6","key":"170_CR24","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00280-013-2286-7","volume":"72","author":"LR Molife","year":"2013","unstructured":"Molife LR, Rudman SM, Alam S, et al. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol. 2013;72(6):1213\u201322.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"170_CR25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjc.6604108","volume":"98","author":"FALM Eskens","year":"2008","unstructured":"Eskens FALM, Mom CH, Planting AST, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98(1):80\u20135.","journal-title":"Br J Cancer"},{"issue":"2","key":"170_CR26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10637-012-9890-y","volume":"31","author":"J Marshall","year":"2013","unstructured":"Marshall J, Hwang J, Eskens FALM, et al. A phase I, open-label, dose escalation study of afatinib, in a 3-week-on\/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):399\u2013408.","journal-title":"Invest New Drugs"},{"issue":"25","key":"170_CR27","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","volume":"28","author":"TA Yap","year":"2010","unstructured":"Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965\u201372.","journal-title":"J Clin Oncol"},{"issue":"2","key":"170_CR28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10637-012-9904-9","volume":"31","author":"MS Gordon","year":"2013","unstructured":"Gordon MS, Mendelson DS, Gross M, et al. A phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):409\u201316.","journal-title":"Invest New Drugs"},{"key":"170_CR29","doi-asserted-by":"crossref","unstructured":"Kristeleit H, Puglisi M, Middleton GW, et al. Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50\u00a0mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy [abstract no. 2613]. J Clin Oncol. 2011;29(15 Suppl 1).","DOI":"10.1200\/jco.2011.29.15_suppl.2613"},{"issue":"12","key":"170_CR30","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40262-013-0091-4","volume":"52","author":"S Wind","year":"2013","unstructured":"Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet. 2013;52(12):1101\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"27","key":"170_CR31","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327\u201334.","journal-title":"J Clin Oncol"},{"issue":"4","key":"170_CR32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00280-011-1803-9","volume":"69","author":"P Stopfer","year":"2012","unstructured":"Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69(4):1051\u201361.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18S","key":"170_CR33","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1200\/jco.2006.24.18_suppl.2074","volume":"24","author":"DB Agus","year":"2006","unstructured":"Agus DB, Terlizzi E, Stopfer P, et al. A phase I dose escalation study of BIBW 2992, and irreversible dual EGFR\/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract]. J Clin Oncol. 2006;24(18S):2074.","journal-title":"J Clin Oncol"},{"issue":"5","key":"170_CR34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","volume":"13","author":"JC-H Yang","year":"2012","unstructured":"Yang JC-H, Shih J-Y, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539\u201348.","journal-title":"Lancet Oncol"},{"key":"170_CR35","doi-asserted-by":"crossref","unstructured":"Wu YL, Zhou C, Hu C-P, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine\/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract no. 8016]. J Clin Oncol. 2013;31(15 Suppl) (plus poster presented at the 49th Annual Meeting of the American Society of Clinical Oncology; 31 May-4 Jun 2013; Chicago (IL)).","DOI":"10.1200\/jco.2013.31.15_suppl.8016"},{"issue":"27","key":"170_CR36","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","volume":"31","author":"JC-H Yang","year":"2013","unstructured":"Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin\/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342\u201350.","journal-title":"J Clin Oncol"},{"key":"170_CR37","doi-asserted-by":"crossref","unstructured":"Geater SL, Zhou C, Hu C-P, et al. LUX-Lung 6: patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations [abstract no. 8061]. J Clin Oncol. 2013;31(15 Suppl) (plus poster presented at the 49th Annual Meeting of the American Society of Clinical Oncology; 31 May\u20134 Jun 2013; Chicago (IL)).","DOI":"10.1200\/jco.2013.31.15_suppl.8061"},{"issue":"Suppl 9","key":"170_CR38","doi-asserted-by":"crossref","first-page":"ix410","DOI":"10.1016\/S0923-7534(20)33845-X","volume":"23","author":"JC Yang","year":"2012","unstructured":"Yang JC, Schuler M, Yamamoto N, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in LUX-Lung 3, a phase III trial of afatinib or cisplatin\/pemetrexed in EGFR mutation-positive lung cancer [abstract no. 1252P]. Ann Oncol. 2012;23(Suppl 9):ix410\u20131.","journal-title":"Ann Oncol"},{"key":"170_CR39","unstructured":"Yang JC-H, Sequist LV, Geater SL, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer [abstract no. O03.05 plus slide presentation]. 15th World Conference on Lung Cancer; 27\u201330 Oct 2013; Sydney."},{"key":"170_CR40","unstructured":"Mok T, Schuler M, Yamamoto N, et al. LUX-Lung 3: afatinib vs. cisplatin and pemetrexed in Asian patients with adenocarcinoma of the lung harbouring an epidermal growth factor receptor mutation [abstract no. HO-003]. 5th Asia Pacific Lung Cancer Conference; 26\u201328 Nov 2012; Fukuoka."},{"issue":"Suppl 11","key":"170_CR41","doi-asserted-by":"crossref","first-page":"xi8","DOI":"10.1016\/S0923-7534(20)31932-3","volume":"23","author":"N Yamamoto","year":"2012","unstructured":"Yamamoto N, Schuler M, O\u2019Byrne K, et al. LUX-Lung 3: afatinib vs. cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harbouring an EGFR mutation [abstract no. PLS-6]. Ann Oncol. 2012;23(Suppl 11):xi8.","journal-title":"Ann Oncol"},{"key":"170_CR42","unstructured":"Schuler M, Yang JC-H, Sequist LV, et al. Efficacy of afatinib vs. chemotherapy in treatment-na\u00efve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease [abstract no. MO07.13 plus slide presentation]. 15th World Conference on Lung Cancer; 27\u201330 Oct 2013; Sydney."},{"key":"170_CR43","unstructured":"Yang JC-H, Sequist LV, O\u2019Byrne KJ, et al. Epidermal growth factor receptor (EGFR)-mediated adverse events in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) treated with afatinib [abstract no. 895]. Eur J Cancer. 2013;49(Suppl 2):S190 (plus poster presented at European Cancer Congress 2013; 27 Sep\u20131 Oct 2013; Amsterdam)."},{"issue":"6","key":"170_CR44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1586\/era.13.31","volume":"13","author":"JC-H Yang","year":"2013","unstructured":"Yang JC-H, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):729\u201336.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"170_CR45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/era.13.30","volume":"13","author":"ME Lacouture","year":"2013","unstructured":"Lacouture ME, Schadendorf D, Chu C-YC, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):721\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl 9","key":"170_CR46","doi-asserted-by":"crossref","first-page":"ix174","DOI":"10.1016\/S0923-7534(20)33072-6","volume":"23","author":"G Goss","year":"2012","unstructured":"Goss G, Lu S, Felip E, et al. LUX-Lung 8: a randomized, open-label, phase III trial of afatinib vs. erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy [abstract no. 509TiP]. Ann Oncol. 2012;23(Suppl 9):ix174.","journal-title":"Ann Oncol"},{"key":"170_CR47","unstructured":"Boehringer Ingelheim Pharmaceuticals. LUX-Lung 8: a phase III trial of afatinib (BIBW 2992) versus erlotinib for the treatment of squamous cell lung cancer after at least one prior platinum based chemotherapy [ClinicalTrials.gov identifier NCT01523587]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01523587 . Accessed 21 Oct 2013."},{"key":"170_CR48","unstructured":"Boehringer Ingelheim Pharmaceuticals. LUX-Lung 7: a phase IIb trial of afatinib (BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung [ClinicalTrials.gov identifier NCT01466660]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01466660 . Accessed 21 Oct 2013."},{"issue":"2","key":"170_CR49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2013.02.021","volume":"81","author":"X Chen","year":"2013","unstructured":"Chen X, Zhu Q, Zhu L, et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 2013;81(2):155\u201361.","journal-title":"Lung Cancer"},{"issue":"Suppl 9","key":"170_CR50","doi-asserted-by":"crossref","first-page":"ix401","DOI":"10.1016\/S0923-7534(20)33838-2","volume":"23","author":"YY Janjigian","year":"2012","unstructured":"Janjigian YY, Smit EF, Horn L, et al. Activity of afatinib\/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors [abstract no. 12270]. Ann Oncol. 2012;23(Suppl 9):ix401.","journal-title":"Ann Oncol"},{"key":"170_CR51","unstructured":"Boehringer Ingelheim Pharmaceuticals. Trial of BIBW 2992 (afatinib)\u00a0+\u00a0cetuximab in non-small cell lung cancer [ClinicalTrials.gov identifier NCT01090011]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01090011 . Accessed 22 Oct 2013."},{"issue":"27","key":"170_CR52","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1200\/JCO.2013.49.8782","volume":"31","author":"CJ Langer","year":"2013","unstructured":"Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013;31(27):3303\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"170_CR53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2012.01.008","volume":"76","author":"J Grev\u00e8 De","year":"2012","unstructured":"De Grev\u00e8 J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2\/neu. Lung Cancer. 2012;76(1):123\u20137.","journal-title":"Lung Cancer"},{"key":"170_CR54","unstructured":"Boehringer Ingelheim Pharmaceuticals. LUX-Breast 2; afatinib in HER2 (human epidermal growth factor receptor)-treatment failures [ClinicalTrials.gov identifier NCT01271725]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01271725 . Accessed 23 Oct 2013."},{"key":"170_CR55","unstructured":"Boehringer Ingelheim Pharmaceuticals. LUX-Breast 3; afatinib alone or in combination with vinorelbine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer suffering from brain metastases [ClinicalTrials.gov identifier NCT01441596]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01441596 . Accessed 23 Oct 2013."},{"key":"170_CR56","unstructured":"Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 1: a phase III trial of afatinib (BIBW2992) versus methotrexate for the treatment of recurrent and\/or metastatic (R\/M) head and neck squamous cell cancer after platinum based chemotherapy [ClinicalTrials.gov identifier NCT01345682]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01345682 . Accessed 23 Oct 2013."},{"key":"170_CR57","unstructured":"Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 2: a phase III trial of afatinib (BIBW 2992) versus placebo for the treatment of head and neck squamous cell cancer after treatment with chemo-radiotherapy [ClinicalTrials.gov identifier NCT01345669]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01345669 . Accessed 23 Oct 2013."},{"key":"170_CR58","unstructured":"Boehringer Ingelheim Pharmaceuticals. LUX-Head&Neck 3: afatinib (BIBW2992) versus methotrexate for the treatment of recurrent and\/or metastatic head and neck squamous cell cancer after platinum based chemotherapy [ClinicalTrials.gov identifier NCT01856478]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01856478 . Accessed 23 Oct 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0170-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0170-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0170-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T06:25:01Z","timestamp":1597386301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0170-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,17]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["170"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0170-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,17]]}}}